ReachMDA New Era of Schizophrenia Disease Management: TAAR1 and M1/M4 Muscarinic Agonist

Step into the next phase of schizophrenia management with this groundbreaking educational opportunity.

The field of schizophrenia (SCZ) management is on the brink of a significant transformation. With an understanding that D2 blockade is no longer the exclusive pathway for treatment, a new era emerges where innovative therapies targeting TAAR1 and M1/M4 muscarinic receptors are at the forefront. This CME program unveils new scientific evidence and advances in drug design that can lead to significant improvements in patient outcomes, quality of life, and even mortality.

Key Bullet Points:

• Credits: 0.25 IPCE credits
• Duration: 15 minutes
• Media Format: Text
• Focus: New pathways for SCZ treatment, moving away from D2 blockade, exploring TAAR1, M1/M4 muscarinic, and 5-HT2A and 5-HT2C receptors, with insights into new drugs like ulotaront and xanomeline
  • Ulotaront: a TAAR1 and 5-HT1A receptor agonist, has distinct modes of action; although it is not a particular D2 receptor inhibitor, it has been demonstrated to increase D2 receptor internalization, resulting in less D2 receptor occupancy without directly blocking the receptor.
  • Xanomeline: M1 and M4 muscarinic receptor agonist; xanomeline was discovered to bind the M4 receptors in the brain during development, inhibiting acetylcholine release and, as a result, dopamine transmission.
• Learning Objectives:
  • Describe the most recent achievements in SCZ research in terms of new and developing science concerning the cellular and molecular processes underpinning SCZ.
  • Distinguish the pharmacodynamics as well as the most recent efficacy and safety clinical trial data linked with new TAAR1 agonists from muscarinic and serotonergic-based medicines.
• Target Audience: Psychiatrists, NPs, PAs, and other clinicians in SCZ management
• Accreditation: GLC and TotalCME, Inc., accredited by ACCME, ACPE, and ANCC

Psychiatry Latest Posts

• Overview of Anticholinergic MedicationsDecember 11, 2024
• Asthma, Anxiety, and StressDecember 5, 2024
• More Clonazepam ODT Recalled Due to Carton Strength MislabelingDecember 4, 2024
• FDA: Montelukast May Impact Brain FunctioningDecember 4, 2024

Did You Know?
Despite affecting only 1 in 300 people globally, schizophrenia is one of the leading causes of disability worldwide.